1. Risk assessment and risk minimization in nanomedicine: A need for predictive, alternative, and 3Rs strategies;Accomasso;Frontiers in Pharmacology,2018
2. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), (2011). NanoDM Report: Biological assessment of medical devices containing nanomaterials, 1–109.
3. American National Standards Institute (ANSI) Nanotechnology Standards Panel (ANSI-NSP) (2019). No Small Feat: ANSI-Nanotechnology Standards Panel Celebrates 15 Years. Available from: https://www.ansi.org/news_publications/news_story?menuid=7&articleid=4169a9d0-86dc-4fe6-9327-289ac848b35e (Accessed 29 April 2021).
4. How reliably can a material be classified as a nanomaterial? Available particle-sizing techniques at work;Babick;Journal of Nanoparticle Research,2016
5. Doxil (R) –- The first FDA-approved nano-drug: Lessons learned;Barenholz;Journal of Controlled Release,2012